Ulcerative colitis and isotretinoin: Is there a causal relationship?

Dear Editor,

We are reporting the case of a 39-year-old woman without toxic habits and with a history of mild mitral valve prolapsed that, after treatment of acne with dermatologist prescribed isotretinoin, consulted because of an increase in the number of bowel movements and bright red blood rectal bleeding after defecating without accompanying anal symptoms.

The analytical study was normal and a colonoscopy was performed. Signs of inflammation were found in the distal 10 cm of rectal mucosal and had an erythematosus and granular appearance with effacement of the submucosal vascular pattern and non-confluent micro-ulcers. All of this is suggestive of ulcerative proctitis (Fig. 1). The histological study showed an alteration in the glandular architecture with a reduction of goblet cells without observing crypt abscesses and with dense inflammatory infiltrate of plasma cells in the lamina propria.

The patient was treated with topical mesalazine via suppository, initially at a dosage of 1 g/12 h and dosage was subsequently continued at 1 g/24 h. There was a clinical response; cessation of rectal bleeding and intestinal rhythm normalisation was observed.

In the three years that the patient has continued follow up at our office, she has shown isolated outbreaks that have been controlled with topical mesalazine treatment, as needed.

Discussion

Some medications have been suggested as the cause or trigger of outbreaks in patients with inflammatory bowel disease (IBD) (1-3). Isotretinoin is a vitamin A analogue indicated in serious acne and whose use has been seen as being involved in the development of IBD (4-7), although information to this regard is not yet clear. In 1986, the first report of a case of a 26-year-old woman who had proctitis during isotretinoin treatment and improved upon withdrawal from this medication was published. Other cases and clinical series (5-7) have been reported since this time. However, the most recent case-control studies do not seem to confirm isotretinoin as having a relevant role in the evolution of IBD. Etminan et al. carried out a case-control study with 45,339 women undergoing oral contraceptive without finding an association between the use of isotretinoin with ulcerative colitis (RR: 0.9, IC 95 %, 0.52-1.90) or with Crohn’s disease (RR: 0.91, IC 95 %, 0.37-2.25), concluding that this medication does not increase the risk of IBD (8). Alhusayen et al. did not find an association with IBD evolution either when carrying out a retrospective
population-based cohort including 46,922 patients treated with isotretinoin (RR 1.14; IC 95 %, 0.92-1.41) (9).

In conclusion, to date, causal relationship between isotretinoin and IBD cannot be definitively established. However, this fact should be taken into account when considering treatment with isotretinoin in patients that have IBD diagnosis and those patients with risk factors for developing this illness.

Rogger Álvaro Bendezú-García, Álvaro Hernández-Martínez, Gustavo Oliver Patrón-Román, Francisco Bravo-Castillo and José Luis Vega-Sáenz

Department of Gastroenterology. Hospital Torrecárdenas, Almería, Spain

References


